Yutaka Kondo

Summary

Affiliation: Aichi Cancer Center
Country: Japan

Publications

  1. pmc Downregulation of histone H3 lysine 9 methyltransferase G9a induces centrosome disruption and chromosome instability in cancer cells
    Yutaka Kondo
    Division of Molecular Oncology, Aichi Cancer Center Research Institute, Nagoya, Japan
    PLoS ONE 3:e2037. 2008
  2. pmc Epigenetic cross-talk between DNA methylation and histone modifications in human cancers
    Yutaka Kondo
    Division of Molecular Oncology, Aichi Cancer Center Research Institute, Nagoya, Japan
    Yonsei Med J 50:455-63. 2009
  3. doi request reprint DNA methylation profiling in cancer
    Yutaka Kondo
    Division of Molecular Oncology, Aichi Cancer Center Research Institute, Nagoya 464 8681, Japan
    Expert Rev Mol Med 12:e23. 2010
  4. doi request reprint Synergistic induction of NY-ESO-1 antigen expression by a novel histone deacetylase inhibitor, valproic acid, with 5-aza-2'-deoxycytidine in glioma cells
    Sachie Oi
    Department of Neurosurgery, Nagoya University School of Medicine, Showa Ku, Nagoya, 466 8550, Japan
    J Neurooncol 92:15-22. 2009
  5. pmc The global DNA methylation surrogate LINE-1 methylation is correlated with MGMT promoter methylation and is a better prognostic factor for glioma
    Fumiharu Ohka
    Department of Neurosurgery, Nagoya University School of Medicine, Nagoya, Japan
    PLoS ONE 6:e23332. 2011
  6. doi request reprint Activated leukocyte cell-adhesion molecule (ALCAM) promotes malignant phenotypes of malignant mesothelioma
    Futoshi Ishiguro
    Division of Molecular Oncology, Aichi Cancer Center Research Institute, Nagoya, Japan
    J Thorac Oncol 7:890-9. 2012
  7. doi request reprint Integrated analysis of genetic and epigenetic alterations reveals CpG island methylator phenotype associated with distinct clinical characters of lung adenocarcinoma
    Keiko Shinjo
    Division of Molecular Oncology, Aichi Cancer Center Research Institute, 1 1 Kanokoden, Chikusa ku, Nagoya 464 8681, Japan
    Carcinogenesis 33:1277-85. 2012
  8. doi request reprint Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma
    Yasuhiro Goto
    Divisions of Molecular Oncology, Aichi Cancer Center Research Institute, Nagoya, Japan
    Cancer Res 69:9073-82. 2009
  9. pmc Contribution of microRNA-1275 to Claudin11 protein suppression via a polycomb-mediated silencing mechanism in human glioma stem-like cells
    Keisuke Katsushima
    Division of Molecular Oncology, Aichi Cancer Center Research Institute, Nagoya 464 8681, Japan
    J Biol Chem 287:27396-406. 2012
  10. doi request reprint Membranous expression of activated leukocyte cell adhesion molecule contributes to poor prognosis and malignant phenotypes of non-small-cell lung cancer
    Futoshi Ishiguro
    Division of Molecular Oncology, Aichi Cancer Center Research Institute, Nagoya, Japan
    J Surg Res 179:24-32. 2013

Detail Information

Publications58

  1. pmc Downregulation of histone H3 lysine 9 methyltransferase G9a induces centrosome disruption and chromosome instability in cancer cells
    Yutaka Kondo
    Division of Molecular Oncology, Aichi Cancer Center Research Institute, Nagoya, Japan
    PLoS ONE 3:e2037. 2008
    ..Cancer cells are characterized by prominent epigenetic dysregulation, including histone modifications. However, the functional roles of the histone methyltransferases (HMT) in cancer remain unclear...
  2. pmc Epigenetic cross-talk between DNA methylation and histone modifications in human cancers
    Yutaka Kondo
    Division of Molecular Oncology, Aichi Cancer Center Research Institute, Nagoya, Japan
    Yonsei Med J 50:455-63. 2009
    ....
  3. doi request reprint DNA methylation profiling in cancer
    Yutaka Kondo
    Division of Molecular Oncology, Aichi Cancer Center Research Institute, Nagoya 464 8681, Japan
    Expert Rev Mol Med 12:e23. 2010
    ..In this review, the current key technologies available to assess genome-wide DNA methylation are introduced and the implications of DNA methylation profiling in human cancers are discussed...
  4. doi request reprint Synergistic induction of NY-ESO-1 antigen expression by a novel histone deacetylase inhibitor, valproic acid, with 5-aza-2'-deoxycytidine in glioma cells
    Sachie Oi
    Department of Neurosurgery, Nagoya University School of Medicine, Showa Ku, Nagoya, 466 8550, Japan
    J Neurooncol 92:15-22. 2009
    ..These findings not only shed light on an epigenetic immunotherapy, but also suggest that the silencing of NY-ESO-1 is mediated by histone modification...
  5. pmc The global DNA methylation surrogate LINE-1 methylation is correlated with MGMT promoter methylation and is a better prognostic factor for glioma
    Fumiharu Ohka
    Department of Neurosurgery, Nagoya University School of Medicine, Nagoya, Japan
    PLoS ONE 6:e23332. 2011
    ..As a global DNA methylation marker, LINE-1 may be a promising marker in gliomas...
  6. doi request reprint Activated leukocyte cell-adhesion molecule (ALCAM) promotes malignant phenotypes of malignant mesothelioma
    Futoshi Ishiguro
    Division of Molecular Oncology, Aichi Cancer Center Research Institute, Nagoya, Japan
    J Thorac Oncol 7:890-9. 2012
    ..However, detailed characteristics of aberrant expression status of cell-adhesion molecules in malignant mesothelioma (MM) cells and their possible biological roles for MM malignancy remain poorly understood...
  7. doi request reprint Integrated analysis of genetic and epigenetic alterations reveals CpG island methylator phenotype associated with distinct clinical characters of lung adenocarcinoma
    Keiko Shinjo
    Division of Molecular Oncology, Aichi Cancer Center Research Institute, 1 1 Kanokoden, Chikusa ku, Nagoya 464 8681, Japan
    Carcinogenesis 33:1277-85. 2012
    ..CIMP classification using our six-marker panel has implications for personalized medical strategies for lung cancer patients; in particular, DNA methylation inhibitor might be of therapeutic benefit to patients with CIMP-positive tumors...
  8. doi request reprint Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma
    Yasuhiro Goto
    Divisions of Molecular Oncology, Aichi Cancer Center Research Institute, Nagoya, Japan
    Cancer Res 69:9073-82. 2009
    ..Our findings show a characteristic epigenetic profile of MPM and uncover multiple distinct epigenetic abnormalities that lead to the silencing of tumor suppressor genes in MPM and could serve as diagnostic or prognostic targets...
  9. pmc Contribution of microRNA-1275 to Claudin11 protein suppression via a polycomb-mediated silencing mechanism in human glioma stem-like cells
    Keisuke Katsushima
    Division of Molecular Oncology, Aichi Cancer Center Research Institute, Nagoya 464 8681, Japan
    J Biol Chem 287:27396-406. 2012
    ..Given that inhibition of miR-1275 induces expression of oligodendroglial lineage proteins and suppresses tumor cell proliferation, this may be a potential therapeutic target for glioblastomas...
  10. doi request reprint Membranous expression of activated leukocyte cell adhesion molecule contributes to poor prognosis and malignant phenotypes of non-small-cell lung cancer
    Futoshi Ishiguro
    Division of Molecular Oncology, Aichi Cancer Center Research Institute, Nagoya, Japan
    J Surg Res 179:24-32. 2013
    ..However, the relationship between ALCAM expression and progression of non-small-cell lung cancer (NSCLC) has not been investigated. This study was designed to clarify the prognostic impact of ALCAM expression of NSCLC cells...
  11. doi request reprint The modulation of microRNAs by type I IFN through the activation of signal transducers and activators of transcription 3 in human glioma
    Masasuke Ohno
    Department of Neurosurgery, Aichi Cancer Center Research Institute, Nagoya 466 8550, Japan
    Mol Cancer Res 7:2022-30. 2009
    ..These results highlight the importance of understanding the transcriptional regulation of the miRNAs involved in oncogenesis...
  12. pmc Distinct profiles of epigenetic evolution between colorectal cancers with and without metastasis
    Hai xing Ju
    Division of Molecular Oncology, Aichi Cancer Center Research Institute, Nagoya, Japan
    Am J Pathol 178:1835-46. 2011
    ..In addition, most methylation status in stage IV CRCs seems to be established before metastasis...
  13. doi request reprint Epigenetic subclassification of meningiomas based on genome-wide DNA methylation analyses
    Yugo Kishida
    Department of Neurosurgery, Nagoya University School of Medicine, 65 Tsurumai Cho, Showa Ku, Nagoya, Aichi 466 8550, Japan
    Carcinogenesis 33:436-41. 2012
    ....
  14. doi request reprint YAP1 is involved in mesothelioma development and negatively regulated by Merlin through phosphorylation
    Toshihiko Yokoyama
    Division of Molecular Oncology, Aichi Cancer Center Research Institute, 1 1 Kanokoden, Chikusa ku, Nagoya 464 8681, Japan
    Carcinogenesis 29:2139-46. 2008
    ..Future studies of transcriptional targets of YAP1 in MPMs may shed light on the molecular mechanisms of MPM development and lead to new therapeutic strategies...
  15. doi request reprint Aberrant DNA methylation associated with aggressiveness of gastrointestinal stromal tumour
    Yasuyuki Okamoto
    Division of Molecular Oncology, Aichi Cancer Center Research Institute, 1 1 Kanokoden, Chikusa ku, Nagoya 464 8681, Japan
    Gut 61:392-401. 2012
    ..Our aim was to establish epigenetic profiles associated with the malignant transformation of GISTs...
  16. doi request reprint Epigenetic aberrations and therapeutic implications in gliomas
    Atsushi Natsume
    Department of Neurosurgery, Nagoya University School of Medicine, Nagoya, Japan
    Cancer Sci 101:1331-6. 2010
    ..Thus, epigenetic therapy may be a promising and potent treatment for human neoplasia...
  17. doi request reprint Variable DNA methylation patterns associated with progression of disease in hepatocellular carcinomas
    Wentao Gao
    Division of Molecular Oncology, Aichi Cancer Center Research Institute, 1 1 Kanokoden, Chikusa ku, Nagoya 464 8681, Japan
    Carcinogenesis 29:1901-10. 2008
    ..Our global epigenome analysis reveals distinct patterns of methylation that are probably to represent different pathophysiologic processes in HCCs...
  18. doi request reprint LATS2 is a tumor suppressor gene of malignant mesothelioma
    Hideki Murakami
    Division of Molecular Oncology, Aichi Cancer Center Research Institute, Nagoya, Japan
    Cancer Res 71:873-83. 2011
    ..Thus, our results suggest that the inactivation of LATS2 is one of the key mechanisms for constitutive activation of YAP, which induces deregulation of MM cell proliferation...
  19. doi request reprint Hepatitis virus infection affects DNA methylation in mice with humanized livers
    Yasuyuki Okamoto
    Division of Epigenomics, Aichi Cancer Center, Nagoya, Japan Division of Molecular Oncology, Aichi Cancer Center, Nagoya, Japan Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medicine, Nagoya, Japan
    Gastroenterology 146:562-72. 2014
    ..Chronic hepatitis has also been associated with aberrant DNA methylation, but little is known about their relationship...
  20. pmc Convergent signaling in the regulation of connective tissue growth factor in malignant mesothelioma: TGFβ signaling and defects in the Hippo signaling cascade
    Makiko Fujii
    Division of Molecular Oncology, Aichi Cancer Center Research Institute, Nagoya, Japan
    Cell Cycle 11:3373-9. 2012
    ..Furthermore, we demonstrated the functional importance of CTGF through the mouse studies and human histological analyses, which may elucidate the clinical features of MM with severe fibrosis in the thoracic cavity...
  21. doi request reprint Correlation between quantified promoter methylation and enzymatic activity of O6-methylguanine-DNA methyltransferase in glioblastomas
    Yugo Kishida
    Department of Neurosurgery, Nagoya University School of Medicine, 65 Tsurumai Cho, Showa Ku, Nagoya, 466 8550, Japan
    Tumour Biol 33:373-81. 2012
    ..The present results indicate that the quantification of MGMT methylation by bisulfite pyrosequencing represents its enzymatic activity and thus, its therapeutic responsiveness to alkylating agents...
  22. pmc TGF-β synergizes with defects in the Hippo pathway to stimulate human malignant mesothelioma growth
    Makiko Fujii
    Division of Molecular Oncology, Aichi Cancer Center Research Institute, Chikusa ku, Nagoya 464 8681, Japan
    J Exp Med 209:479-94. 2012
    ..These data suggest that CTGF is an important modulator of MM growth and pathology and represents a novel therapeutic target for this disease...
  23. doi request reprint Activation of the PI3K-AKT pathway in human malignant mesothelioma cells
    Yutaro Suzuki
    Division of Molecular Oncology, Aichi Cancer Center Research Institute, Nagoya 464 8681, Japan
    Mol Med Report 2:181-8. 2009
    ..These findings suggest that AKT is frequently activated in MM cells, in part due to the downregulation of PTEN. Thus, the PI3K-AKT signaling pathway is a potential therapeutic target for MM...
  24. doi request reprint Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells
    Koji Kawaguchi
    Division of Molecular Oncology, Aichi Cancer Center Research Institute, 1 1 Kanokoden, Chikusa ku, Nagoya, Japan
    Carcinogenesis 30:1097-105. 2009
    ....
  25. doi request reprint Benefits of interferon-β and temozolomide combination therapy for newly diagnosed primary glioblastoma with the unmethylated MGMT promoter: A multicenter study
    Kazuya Motomura
    Department of Neurosurgery, Nagoya University School of Medicine, Nagoya, Japan
    Cancer 117:1721-30. 2011
    ..The aim of the current study was to catalog genomic and epigenomic abnormalities in newly diagnosed glioblastoma patients and determine the correlation among clinical, genetic, and epigenetic profiles and clinical outcome...
  26. ncbi request reprint [Epigenetic analyses of brain tumor stem cells]
    Atsushi Natsume
    Department of Neurosurgery, Nagoya University School of Medicine, 65 Tsurumai Cho, Showa Ku, Nagoya, Aichi 466 8550, Japan
    Brain Nerve 61:791-8. 2009
    ..In addition, we considered the prospects for developing epigenetic therapies...
  27. doi request reprint Induction of oligodendrogenesis in glioblastoma-initiating cells by IFN-mediated activation of STAT3 signaling
    Kanako Yuki
    Center for Genetic and Regenerative Medicine, Nagoya University Hospital, Nagoya, Japan
    Cancer Lett 284:71-9. 2009
    ..Therefore, IFN may be a potential therapeutic agent for inducing the terminal differentiation of GICs...
  28. ncbi request reprint [Targeting epigenetics plasticity as a novel target for human neoplasia]
    Keiko Shinjo
    Division of Molecular Oncology, Aichi Cancer Center Research Institute, Chikusa ku, Nagoya, Japan
    Gan To Kagaku Ryoho 37:1654-8. 2010
    ..The reversible nature of epigenetic changes has led to the emergence of the field of epigenetic therapy, which may lead to potent and promising cancer treatment...
  29. doi request reprint RASSF3 downregulation increases malignant phenotypes of non-small cell lung cancer
    Asuki Fukatsu
    Division of Molecular Oncology, Aichi Cancer Center Research Institute, 1 1 Kanokoden, Chikusa ku, Nagoya 464 8681, Japan Department of Respiratory Medicine, Graduate School of Medicine, Nagoya University, Nagoya 466 8550, Japan
    Lung Cancer 83:23-9. 2014
    ..Recently, we found that RASSF3 interacts with MDM2 and facilitates its ubiquitination, which induces apoptosis through p53 stabilization. However, the role of RASSF3 in human malignancies remains largely unknown...
  30. pmc Epigenetic histone modification of Epstein-Barr virus BZLF1 promoter during latency and reactivation in Raji cells
    Takayuki Murata
    Division of Virology, Aichi Cancer Center Research Institute, Kanokoden, Chikusa ku, Nagoya, Japan
    J Virol 86:4752-61. 2012
    ....
  31. doi request reprint Clinical implications of epigenetic alterations in human thoracic malignancies: epigenetic alterations in lung cancer
    Keiko Shinjo
    Division of Molecular Oncology, Aichi Cancer Center Research Institute, Chikusa ku, Nagoya, Japan
    Methods Mol Biol 863:221-39. 2012
    ..In this chapter, studies of epigenetic abnormality and its clinical implication in lung cancers are discussed...
  32. doi request reprint The DNA demethylating agent 5-aza-2'-deoxycytidine activates NY-ESO-1 antigenicity in orthotopic human glioma
    Atsushi Natsume
    Department of Neurosurgery, Nagoya University School of Medicine, Nagoya, Japan
    Int J Cancer 122:2542-53. 2008
    ..These results suggested that 5-aza-CdR induces the expression of epigenetically silenced CTAs in poorly immunogenic gliomas and thereby presents a new strategy for tumor immunotherapy targeting 5-aza-CdR-induced CTAs...
  33. doi request reprint Roles of achaete-scute homologue 1 in DKK1 and E-cadherin repression and neuroendocrine differentiation in lung cancer
    Hirotaka Osada
    Division of Molecular Oncology, Aichi Cancer Center Research Institute, Nagoya 464 8681, Japan
    Cancer Res 68:1647-55. 2008
    ....
  34. doi request reprint Characteristic methylation profile in CpG island methylator phenotype-negative distal colorectal cancers
    Byonggu An
    Division of Molecular Oncology, Aichi Cancer Center Research Institute, Chikusa ku, Nagoya 464 8681, Japan
    Int J Cancer 127:2095-105. 2010
    ....
  35. ncbi request reprint RhoB is frequently downregulated in non-small-cell lung cancer and resides in the 2p24 homozygous deletion region of a lung cancer cell line
    Naohito Sato
    Division of Molecular Oncology, Aichi Cancer Center Research Institute, Nagoya, Japan
    Int J Cancer 120:543-51. 2007
    ..The present study demonstrates that RhoB expression is frequently downregulated in NSCLCs by multiple mechanisms, suggesting that RhoB is a candidate TSG for NSCLC...
  36. doi request reprint Phase I/II study of decitabine in patients with myelodysplastic syndrome: a multi-center study in Japan
    Yasuhiro Oki
    Department of Hematology and Cell Therapy, Aichi Cancer Center Hospital, Nagoya, Japan
    Cancer Sci 103:1839-47. 2012
    ..In summary, decitabine was safe and demonstrated efficacy in Japanese patients with high-risk MDS. This trial was registered at ClinicalTrials.gov (NCT00796003)...
  37. ncbi request reprint Alterations of DNA methylation and histone modifications contribute to gene silencing in hepatocellular carcinomas
    Yutaka Kondo
    Division of Molecular Oncology, Aichi Cancer Center Research Institute, Aichi, Japan
    Hepatol Res 37:974-83. 2007
    ..01). Conclusion: These data suggest that multiple epigenetic silencing mechanisms are inappropriately active in HCC cells...
  38. ncbi request reprint Epigenetic changes in colorectal cancer
    Yutaka Kondo
    Department of Leukemia, University of Texas at M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Metastasis Rev 23:29-39. 2004
    ..Understanding epigenetic alterations as a driving force in neoplasia opens new fields of research in epidemiology, risk assessment, and treatment in CRCs...
  39. pmc Genome-wide profiling of DNA methylation reveals a class of normally methylated CpG island promoters
    Lanlan Shen
    Department of Leukemia, The University of Texas at M D Anderson Cancer Center, Houston, Texas, USA
    PLoS Genet 3:2023-36. 2007
    ....
  40. ncbi request reprint Reactivation of the silenced and imprinted alleles of ARHI is associated with increased histone H3 acetylation and decreased histone H3 lysine 9 methylation
    Satoshi Fujii
    Department of Experimental Therapeutics, The University of Texas, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Hum Mol Genet 12:1791-800. 2003
    ....
  41. pmc Critical role of histone methylation in tumor suppressor gene silencing in colorectal cancer
    Yutaka Kondo
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Mol Cell Biol 23:206-15. 2003
    ..Our results suggest that reduced H3 Lys-4 methylation and increased H3 Lys-9 methylation play a critical role in the maintenance of promoter DNA methylation-associated gene silencing in colorectal cancer...
  42. pmc Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer
    Lanlan Shen
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030
    Proc Natl Acad Sci U S A 104:18654-9. 2007
    ..Together, our integrated genetic and epigenetic analysis reveals that colon cancers correspond to three molecularly distinct subclasses of disease...
  43. doi request reprint Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation
    Yutaka Kondo
    Department of Leukemia, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
    Nat Genet 40:741-50. 2008
    ..These data establish EZH2-mediated H3K27triM as a mechanism of tumor-suppressor gene silencing in cancer that is potentially independent of promoter DNA methylation...
  44. ncbi request reprint RIL, a LIM gene on 5q31, is silenced by methylation in cancer and sensitizes cancer cells to apoptosis
    Yanis A Boumber
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, 1515 Holcombe, Houston, TX 77030, USA
    Cancer Res 67:1997-2005. 2007
    ..In MDS, RIL methylation is a marker of adverse prognosis independent of chromosome 5 and 7 deletions. Our data suggest that RIL is a good candidate TSG silenced by hypermethylation in cancer...
  45. ncbi request reprint MGMT promoter methylation and field defect in sporadic colorectal cancer
    Lanlan Shen
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Natl Cancer Inst 97:1330-8. 2005
    ..The DNA repair gene O6-methylguanine-DNA methyltransferase (MGMT) is frequently methylated in colorectal cancer. We hypothesized that MGMT methylation could be one of the mediators of field cancerization in the colon mucosa...
  46. pmc Chromatin immunoprecipitation microarrays for identification of genes silenced by histone H3 lysine 9 methylation
    Yutaka Kondo
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Proc Natl Acad Sci U S A 101:7398-403. 2004
    ..This unbiased approach confirms the tight coupling between DNA methylation and histone modifications in cancer and could be used to probe gene silencing in nonneoplastic conditions as well...
  47. pmc Epigenetic-genetic interactions in the APC/WNT, RAS/RAF, and P53 pathways in colorectal carcinoma
    Yutaka Suehiro
    Department of Pathology, Division of Pathology and Laboratory Medicine, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Cancer Res 14:2560-9. 2008
    ....
  48. ncbi request reprint PPARgamma-active triterpenoid CDDO enhances ATRA-induced differentiation in APL
    Yoko Tabe
    Section of Molecular Hematology and Therapy, Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Cancer Biol Ther 6:1967-77. 2007
    ..In summary, these results provide rationale for the combined targeting of RAR and PPARgamma nuclear receptors in the therapy of APL...
  49. ncbi request reprint Hypermethylation and silencing of the putative tumor suppressor Tazarotene-induced gene 1 in human cancers
    Emile M Youssef
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 64:2411-7. 2004
    ..These findings indicate that silencing of TIG1 promoter by hypermethylation is common in human cancers and may contribute to the loss of retinoic acid responsiveness in some neoplastic cells...
  50. ncbi request reprint Drug sensitivity prediction by CpG island methylation profile in the NCI-60 cancer cell line panel
    Lanlan Shen
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 67:11335-43. 2007
    ..Our results confirm that epigenetic profiles are useful in identifying molecular mediators for cancer drug sensitivity (pharmaco-epigenomics)...
  51. ncbi request reprint PRDM5 identified as a target of epigenetic silencing in colorectal and gastric cancer
    Yoshiyuki Watanabe
    Department of Molecular Biology, Cancer Research Institute, Sapporo Medical University, Sapporo, Japan
    Clin Cancer Res 13:4786-94. 2007
    ..The aim of the present study was to begin to examine the involvement of epigenetic alteration of PRDM expression in gastric and colorectal cancer...
  52. ncbi request reprint Aberrant DNA methylation of p57KIP2 identifies a cell-cycle regulatory pathway with prognostic impact in adult acute lymphocytic leukemia
    Lanlan Shen
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 101:4131-6. 2003
    ..02). Our results indicate that p57KIP2 is frequently methylated in adult patients with ALL, and that inactivation of a pathway composed of p73, p15, and p57KIP2 predicts for poor prognosis in Ph-negative patients...
  53. ncbi request reprint Lack of p21(CIP1) DNA methylation in acute lymphocytic leukemia
    Lanlan Shen
    Blood 100:3432-3; author reply 3433-4. 2002
  54. pmc An Sp1/Sp3 binding polymorphism confers methylation protection
    Yanis A Boumber
    Department of Leukemia, MD Anderson Cancer Center, University of Texas, Houston, Texas, United States of America
    PLoS Genet 4:e1000162. 2008
    ..Our finding demonstrates that, in some genes, hypermethylation in cancer is dictated by protein-DNA interactions at the promoters and provides a novel mechanism by which genetic polymorphisms can influence an epigenetic state...
  55. ncbi request reprint P14 methylation in human colon cancer is associated with microsatellite instability and wild-type p53
    Lanlan Shen
    Department of Leukemia, The University of Texas at M D Anderson Cancer Center, Houston, Texas 77030, USA
    Gastroenterology 124:626-33. 2003
    ..The p14 (ARF) gene on chromosome 9p is deleted and/or silenced by hypermethylation in a subset of human malignancies. There is evidence suggesting that p14 suppresses tumorigenicity by stabilizing the p53 protein...
  56. ncbi request reprint Enrichment for histone H3 lysine 9 methylation at Alu repeats in human cells
    Yutaka Kondo
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Biol Chem 278:27658-62. 2003
    ..Thus H3-Lys9 methylation is enriched at human repetitive elements, particularly Alu elements, and may play a role in the suppression of recombination by these elements...
  57. ncbi request reprint PML-RARalpha and AML1-ETO translocations are rarely associated with methylation of the RARbeta2 promoter
    Yoko Tabe
    Section of Molecular Hematology and Therapy, Department of Blood and Marrow Transplantation, The University of Texas M D Anderson Cancer Center, 1400 Holcombe Boulevard, Unit 448, Houston, TX 77030, USA
    Ann Hematol 85:689-704. 2006
    ..These results demonstrate that oncogenic PML-RARalpha and AML1-ETO translocations are rarely associated with RARbeta2 promoter methylation in primary AML samples...
  58. pmc A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements
    Allen S Yang
    Department of Leukemia, M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Nucleic Acids Res 32:e38. 2004
    ..This method can be used as a surrogate marker of genome-wide methylation changes. In addition, it is less labor intensive and requires less DNA than previous methods of assessing global DNA methylation...